Information Provided By:
Fly News Breaks for February 14, 2020
Feb 14, 2020 | 07:48 EDT
SunTrust analyst Robyn Karnauskas raised her price target on BioXcel Therapeutics to $150 after updating her model with added sales for opioid withdrawal as well as dementia/schizo/bipolar treatments. The analyst contends that with two pivotal trials and two Phase 2s trials taking place this year, investors are "missing how quickly these data sets will come and also how quickly the company can complete additional Phase 3 trials". Karnauskas is keeping her Buy rating on BioXcel Therapeutics given its expected catalyst-rich 2020.